tetano
Editor, Senior Moderator
Int J Biol Macromol
. 2023 Mar 10;123979.
doi: 10.1016/j.ijbiomac.2023.123979. Online ahead of print.
Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines
Dongliang Wang[SUP] 1 [/SUP], Youqing Yuan[SUP] 2 [/SUP], Bin Liu[SUP] 3 [/SUP], Neal D Epstein[SUP] 4 [/SUP], Yi Yang[SUP] 5 [/SUP]
Affiliations
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shaken the global health system. Various nanotechnology-based strategies for vaccine development have played pivotal roles in fighting against SARS-CoV-2. Among them, the safe and effective protein-based nanoparticle (NP) platforms display a highly repetitive array of foreign antigens on their surface, which is urgent for improving the immunogenicity of vaccines. These platforms greatly improved antigen uptake by antigen presenting cells (APCs), lymph node trafficking, and B cell activation, due to the optimal size, multivalence, and versatility of NPs. In this review, we summarize the advances of protein-based NP platforms, strategies of antigen attachment, and the current progress of clinical and preclinical trials in the development of SARS-CoV-2 vaccines based on protein-based NP platforms. Importantly, the lessons learnt and design approaches developed for these NP platforms against SARS-CoV-2 also provide insights into the development of protein-based NP strategies for preventing other epidemic diseases.
Keywords: COVID-19; Infectious diseases; Nanoparticle vaccine; SARS-CoV-2; Virus-like particles (VLPs).
. 2023 Mar 10;123979.
doi: 10.1016/j.ijbiomac.2023.123979. Online ahead of print.
Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines
Dongliang Wang[SUP] 1 [/SUP], Youqing Yuan[SUP] 2 [/SUP], Bin Liu[SUP] 3 [/SUP], Neal D Epstein[SUP] 4 [/SUP], Yi Yang[SUP] 5 [/SUP]
Affiliations
- PMID: 36907305
- DOI: 10.1016/j.ijbiomac.2023.123979
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shaken the global health system. Various nanotechnology-based strategies for vaccine development have played pivotal roles in fighting against SARS-CoV-2. Among them, the safe and effective protein-based nanoparticle (NP) platforms display a highly repetitive array of foreign antigens on their surface, which is urgent for improving the immunogenicity of vaccines. These platforms greatly improved antigen uptake by antigen presenting cells (APCs), lymph node trafficking, and B cell activation, due to the optimal size, multivalence, and versatility of NPs. In this review, we summarize the advances of protein-based NP platforms, strategies of antigen attachment, and the current progress of clinical and preclinical trials in the development of SARS-CoV-2 vaccines based on protein-based NP platforms. Importantly, the lessons learnt and design approaches developed for these NP platforms against SARS-CoV-2 also provide insights into the development of protein-based NP strategies for preventing other epidemic diseases.
Keywords: COVID-19; Infectious diseases; Nanoparticle vaccine; SARS-CoV-2; Virus-like particles (VLPs).